Labcorp introduces two new blood-based diagnostics for cancer detection, presenting positive growth opportunities.

From Nasdaq: 2025-04-23 17:11:00

Labcorp expands precision oncology offerings with Labcorp Plasma Detect for colon cancer recurrence risk assessment and PGDx elio plasma focus Dx for pan-solid tumors. Labcorp Plasma Detect uses whole-genome sequencing to detect circulating tumor DNA, aiding in early cancer recurrence detection. PGDx elio plasma focus Dx is the first FDA-authorized liquid biopsy kit for targeted therapy in solid tumors. Both tests offer rapid results and improved treatment decision-making. Labcorp will present data on these innovations at the AACR 2025 Annual Meeting. LH stock closed at $224.14, up 1.77%, on Wednesday.



Read more at Nasdaq: Labcorp Expands Precision Oncology Portfolio With Two Innovative Blood-Based Diagnostics